2023 World Conference on Lung Cancer (Posters)-P2.01. The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC

P2.01. The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the safety and efficacy of a treatment approach for locally advanced non-small cell lung cancer (NSCLC) using induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy. The study aimed to provide an alternative treatment option for patients who are not candidates for concurrent chemoradiation therapy due to poor performance status or large tumor burden. <br /><br />The study included patients with previously untreated, unresectable stage III NSCLC, who were EGFR/ALK-wild-type and had measurable disease. Patients received three cycles of chemotherapy (carboplatin, paclitaxel for squamous NSCLC or pemetrexed for non-squamous NSCLC) and tislelizumab, followed by thoracic radiotherapy. Consolidation tislelizumab was given for up to 14 additional cycles or until intolerable adverse events occurred.<br /><br />The results showed promising antitumor activity of the treatment approach. The 12-month progression-free survival rate was 86.7%, and the objective response rate was 86.7%. The disease control rate was 96.7%. Grade 3 to 5 pneumonitis, a potential side effect of the treatment, occurred in 3.3% of patients. Treatment-related adverse events of any grade were reported in 86.7% of patients, with grade 3 to 4 events in 20.0% of patients. No grade 5 treatment-related adverse events were reported.<br /><br />In conclusion, the study suggests that induction chemoimmunotherapy followed by radiotherapy and consolidation immunotherapy is a promising treatment approach for locally advanced NSCLC. The treatment showed antitumor activity and manageable safety profile in this patient population. This alternative approach could benefit patients who are not suitable for concurrent chemoradiation therapy due to poor performance status or large tumor burden.

Asset Subtitle

Min Tang

Meta Tag

Speaker Min Tang

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

locally advanced non-small cell lung cancer

NSCLC

induction chemoimmunotherapy

radiotherapy

consolidation immunotherapy

chemoradiation therapy

performance status

tumor burden

progression-free survival rate

antitumor activity